ArticleInternational journal of colorectal disease2015
The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer.
Article in International journal of colorectal disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 7 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in colorectal cancer: a meta-analysis.Annals of medicine · 2025Pooled it
- The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Pooled it
- The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis.Oncotarget · 2017Pooled it
- An Elevated Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis.Disease markers · 2017Pooled it
- Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer.Oncotarget · 2016Pooled it
- Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis.Medicine · 2016Pooled it
- Hematological markers as prognostic predictors in patients undergoing colon cancer surgery.Scientific reports · 2025Article
- Novel immune-nutritional prognostic ratio predicts long-term survival in stage I-III colorectal cancer.Frontiers in oncology · 2025Article
- The Impact of Hematologic Parameters on Histopathologic Features of Colorectal Cancer.International journal of general medicine · 2024Article
- Inflammatory Response Markers as Predictors of Colorectal Cancer Prognosis.Ewha medical journal · 2023Review
- Article
- The Pre-Treatment Platelet-to-Lymphocyte Ratio as a Prognostic Factor for Loco-Regional Control in Locally Advanced Rectal Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis.Frontiers in surgery · 2023Review
- Analysis of Risk Factors for Early Progression of Prostate Cancer After Initial Endocrine Therapy.Journal of Cancer · 2023Article
- Pretreatment inflammatory markers predicting treatment outcomes in colorectal cancer.Annals of coloproctology · 2022Review
- Article
- Abilities of Pre-Treatment Inflammation Ratios as Classification or Prediction Models for Patients with Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- Exploring the value of new preoperative inflammation prognostic score: white blood cell to hemoglobin for gastric adenocarcinoma patients.BMC cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe platelet to lymphocyte ratio (PLR) is a potential prognostic marker in a number of different cancers. The aim of this study was to evaluate the prognostic impact of the PLR in patients with stage II colorectal cancer (CRC) who have undergone curative resection but not adjuvant chemotherapy.
methodsA retrospective review was performed on 234 patients with stage II CRC who underwent curative resection, but not adjuvant chemotherapy, in our institute. The patients were divided into low and high PLR groups, and patient survival as well as several clinicopathological factors were compared between the groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were analyzed by using the Kaplan-Meier method, and multivariate analysis was performed by using the Cox proportional hazard model.
resultsThe cutoff value of the PLR determined by using a receiver-operating characteristic curve analysis was 25.4. DFS and CSS were significantly better in patients with a low PLR compared to patients with a high PLR (P = 0.002 and P = 0.011, respectively). On multivariate analysis, we identified the PLR as an independent prognostic factor for DFS and CSS, with a hazard ratio of 2.65 (95 % confidence interval [CI], 1.26-5.45; P = 0.011) and 3.61 (95 % CI, 1.08-12.64; P = 0.038, respectively).
conclusionsThe PLR is a good prognostic indicator in patients with stage II CRC who have undergone curative surgery but not adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.